Submitted by Nicola-Swanborough on Tue, 03/09/2019 - 11:17
Why NICE is right to be cautious about recommending medicinal cannabis for two childhood epilepsy syndromes. Our medical director, Professor Ley Sander writes.
Submitted by olivia-rzadkiewicz on Mon, 13/06/2016 - 16:52
The second Phase 3 clinical trial is to begin for ZX008, a branded version of low-dose fenfluramine, designed as an adjunctive treatment of seizures in children with Dravet syndrome.
Submitted by olivia-rzadkiewicz on Tue, 12/04/2016 - 16:17
GW Pharmaceuticals has announced the start of a Phase 3 clinical trial of Epidiolex® (a cannabidiol-based medication) as an adjunctive therapy for the treatment of epileptic seizures in the rare genetic disorder tuberous sclerosis complex (TSC).
Submitted by Nicola-Swanborough on Fri, 18/03/2016 - 13:20
Eleven-year-old girl with a rare form of childhood epilepsy steals show when she takes the Duchess of Cambridge on an impromptu tour of a new charity shop.